Morgan Keegan has published a report on AtriCure ATRC after a grant to develop minimally invasive surgical technology.
In the report, Morgan Keenan comments, "We think AtriCure shares are currently traded near fair value. Using a 10-year DCF and EV/Sales, AtriCure shares appear fairly valued in the range of $14 $15. Based on a 40% weighting of our DCF value and a 60% weighting of our EV/Sales value, we arrive at a blended valuation of $14 which is near the current stock price."
Morgan Keenan rated AtriCure a Market Perform with a price target of $14.00. AtriCure closed Friday at $13.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in